Active Psoriatic Arthritis Clinical Trial
Official title:
A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA)
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.
The study is intended to evaluate the safety and efficacy of BMS-986165 Dose A or B once daily (QD) compared with placebo in adults with active PsA. The primary endpoint is american college of rheumatology (ACR) 20 response at Week 16 (Part A). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03357471 -
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
|
Phase 3 | |
| Recruiting |
NCT04314544 -
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
|
Phase 3 | |
| Active, not recruiting |
NCT04314531 -
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
|
Phase 3 | |
| Withdrawn |
NCT05499416 -
Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis
|
Phase 4 | |
| Recruiting |
NCT04876781 -
Korean Post-marketing Surveillance for Xeljanz XR
|
||
| Completed |
NCT02980692 -
Efficacy and Safety Study of SUNPG1623
|
Phase 2 |